If science could decelerate the impact of aging?
Could science slow down aging? Preventive targeting of modifiable mechanisms of aging may be possible in the future.
Aging is being recognized as a targetable condition, with more funding and focus on aging research and initiatives.
The TAME trial is an example of a clinical trial approved by the FDA targeting aging. The NIH increased its budget for aging-related research and conditions from $2.6 billion in 2014 to $5.7 billion in 2021.
Venture capital is also increasing investment in anti-aging research. Companies such as BioAge Labs are studying centenarians' longitudinal data to understand the factors underpinning a long and healthy life.
Eric Verdin from the Buck Institute said that targeting aging is actually targeting the biggest risk pathway for diseases and that there are pathways that control the aging rate.
Dialing these pathways up or down can change life expectancy and health span.